CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 69 enrolled
Drug / intervention
Concurrent chemotherapy +2 moredrug
Likely dose
Concurrent chemotherapy 25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03659578
NCT03659578Phase 2Completed
CompareCT.gov

A Phase II Study of Thymopeptide a1 During Split-course Chemoradiotherapy to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

Sun Yat-sen University·interventional·Posted Sep 6, 2018·Updated Jan 3, 2022

In Brief

A Phase 2 clinical trial evaluating Concurrent chemotherapy, split-course radiotherapy, and 1 other intervention for Non-small Cell Lung Cancer. Completed, enrolled 69 participants across 1 site.

Detailed Summary

This Phase II study is to determine the efficacy of Thymosin α1 on the frequency of acute pneumonia in non-small cell lung cancer with bulky tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 6, 2018
Enrollment StartAug 9, 2018
Primary CompletionSep 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.8 years ago

Interventions

Concurrent chemotherapydrug

Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.

split-course radiotherapyradiation

Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost

thymosin alpha 1drug

subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.